XYLOCAINE WITH EPINEPHRINE INJECTION Rx
Generic Name and Formulations:
Lidocaine HCl 5mg/mL with epinephrine 1:200000, 10mg/mL with epinephrine 1:100000, 20mg/mL with epinephrine 1:100000; soln; contains methylparaben, sodium metabisulfite.
Fresenius Kabi USA
Indications for XYLOCAINE WITH EPINEPHRINE INJECTION:
Local or regional anesthesia for infiltration and nerve block (see full labeling).
See full labeling for recommended doses based on procedures. When larger volumes are required, only solutions containing epinephrine should be used except where vasopressors are contraindicated. Caudal and lumbar epidural block: administer test dose; epinephrine may serve as a warning of unintentional intravascular inj. For all procedures: max dose: 7mg/kg, not to exceed 500mg. Elderly, debilitated, cardiac and/or liver disease: reduce dose.
Max dose determined by age and weight. See full labeling for specific dosages based on procedures.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Intra-articular infusions: not recommended. Avoid intravascular inj. Avoid methylparaben with spinal or epidural anesthesia. Monitor cardiovascular and respiratory vital signs. Severe shock. Heart block. Neurological disease. Spinal deformities. Septicemia. Severe hypertension. Peripheral or hypertensive vascular disease. Hepatic disease. Impaired cardiovascular function. Malignant hyperthermia. Head and neck administration. Discontinue if severe anaphylactic reactions occur. Labor & delivery: see full labeling. Pregnancy (Cat.B). Nursing mothers.
Concurrent during or after potent general anesthetic agents may cause cardiac arrhythmias; use caution. Concurrent vasopressor and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Severe prolonged hypertension with MAOIs or tricyclic antidepressants. Phenothiazines and butyrophenones antagonize pressor effect of epinephrine; avoid.
Local anesthetic + vasoconstrictor.
CNS effects (eg, lightheadedness, confusion), cardiovascular effects (eg, bradycardia, hypotension, cardiovascular collpase), allergic reactions, headache, backache, nausea, increased creatinine phosphokinase.
Multi-dose vials (10mL)—1, 5; Multi-dose vials (20mL, 50mL)—1; MPF ampules (5mL)—10; MPF ampules (20mL, 30mL)—5; MPF single-dose vials (10mL)—5; MPF single-dose vials (20mL, 30mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma